Author: Ravi Shankar

VANCOUVER, British Columbia, Sept. 21, 2026 (GLOBE NEWSWIRE) — Brutus Mining Inc. (“Brutus” or the “Company”) (CSE: BRU) announces that it proposes to undertake two concurrent non-brokered private placements for combined gross proceeds of up to approximately $3,000,000 (together, the “Offerings”): a hard dollar unit (each, a “Unit”) offering (the “Unit Offering”) and a flow-through unit (each, a “FT Unit”) offering (the “FT Offering”).

Each Unit will be sold at a price of $0.35 per Unit, for up to 5,714,285 Units and gross proceeds of up to $1,999,999.75. Each Unit will consist of one (1) common share of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one Share at a price of $0.40 for a period of 24 months from the closing date.

Each FT Unit will be sold at a price of $0.40 per FT Unit, for up to 2,500,000 FT Units and gross proceeds of up to $1,000,000. Each FT Unit will consist of one (1) common share of the Company issued as a “flow-through share” within the meaning of the Income Tax Act (Canada) (a “FT Share”) and one common share purchase warrant (a “FT Warrant”). Each FT Warrant will entitle the holder to purchase one Share, which will not be a flow-through share, at a price of $0.43 for a period of 24 months from the closing date.

The Company intends to use the proceeds of the Unit Offering for exploration on the CW Property, the evaluation of new project opportunities and for general working capital purposes. The Units will be offered to qualified investors in reliance upon exemptions from the prospectus and registration requirements of applicable securities legislation. A portion of the Unit Offering may be completed in accordance with the exemption set out in BC Instrument 45–536 Exemption from prospectus requirement for certain distributions through an investment dealer and the corresponding blanket orders and rules in the other Canadian jurisdictions that have adopted the same or a similar exemption from the prospectus requirement (collectively, the “Investment Dealer Exemption“). The Investment Dealer Exemption is available in each of Alberta, British Columbia, Saskatchewan, Manitoba and New Brunswick to a person or company who has obtained advice regarding the suitability of the investment from a person registered as an investment dealer in such person’s or company’s jurisdiction. As required by the Investment Dealer Exemption, the Company confirms that, as of the date of this press release, there is no “material fact” or “material change” (as those terms are defined under applicable securities laws) related to the Company which has not been generally disclosed. The gross proceeds of the FT Offering will be used to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures” (as those terms are defined in the Income Tax Act (Canada)) (the “Qualifying Expenditures”) on the CW Property. The Company will renounce all Qualifying Expenditures to the subscribers of the FT Units with an effective date no later than December 31, 2026.

The Company will pay finders’ fees to eligible finders in connection with the Offerings, subject to compliance with applicable securities laws and the policies of the Canadian Securities Exchange. There will be a hold period of four months and one day on all securities issued under the Offerings.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Brutus Mining Inc.

Brutus Mining Inc. (CSE: BRU) is a Vancouver-based mineral exploration company. Its sole mineral property interest is an option to acquire a 100% interest in the CW Property, five contiguous mineral claims totalling 2,894.56 hectares in the Kamloops Mining Division of British Columbia, approximately 100 kilometres north of Kamloops. The Property hosts five reported MINFILE showings with copper and gold mineralization and is at an early stage of exploration. No mineral resources or mineral reserves have been estimated on the Property.

On Behalf of the Board of Directors

Christos Doulis
Chief Executive Officer, Director
+1 (604) 636-7335
info@brutusmining.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Maxus’, future growth potential for Maxus and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of copper, gold, tungsten, antimony and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Maxus’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Offerings and the intended use of proceeds therefrom; the Company’s objectives, goals or future plans; the commencement of drilling or exploration programs in the future; the completion of the Offerings. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of copper, gold, tungsten, antimony and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SANTA CLARA, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that members of its executive leadership team will participate in an Investor Breakfast Presentation during SEMICON West on Tuesday, Oct. 13, 2026. The presentation will begin at 8:00 a.m. PT and will conclude at approximately 10:30 a.m. PT.

A live webcast will be available on the Applied Materials website at: https://ir.appliedmaterials.com with a replay available the same day.

About Applied Materials
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions that are at the foundation of virtually every new semiconductor and advanced display in the world. The technology we create is essential to advancing AI and accelerating the commercialization of next-generation chips. At Applied, we push the boundaries of science and engineering to deliver material innovation that changes the world. Learn more at www.appliedmaterials.com.

Contact:
Ricky Gradwohl (editorial/media) 408.235.4676
Mike Sullivan (financial community) 408.986.7977

“Fuel Made-in-Europe, for Europe”: Skid-mounted module readies for Portugal deployment as HyOrc targets expansion across 11 major European port hubs

HOUSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) — HyOrc Corporation (OTCQB: HYOR), an emerging clean-energy infrastructure company today announced the completion of modular off-site fabrication and assembly for its first commercial waste to methanol module. Shown below.

The modular plant is now preparing for factory testing and then transport to Portugal, establishing HyOrc’s commercial footprint in Europe.

Engineered to process approximately three tonnes-per-day of RDF—non-recyclable municipal and industrial waste—the system is designed to yield up-to one tonne-per-day of chemical-grade green methanol. By transforming domestic waste liabilities into high-value liquid fuels on European soil, HyOrc provides an industrial bridge between waste and maritime decarbonization.

Modular Skid Architecture. Our units are designed to be fully constructed and tested off-site as integrated, skid-mounted assemblies. This pre-commissioning modular approach materially reduces on-site civil works, streamlines portside integration, and minimizes installation timelines. The underlying conversion pathway—spanning gasification, syngas cleaning, conditioning, and methanol synthesis—builds upon testing witnessed and independently verified with zero non-conformities by Bureau Veritas.

Porto First. Europe’s Maritime Ports Next. The Porto deployment represents the baseline commercial blueprint for HyOrc’s modular replication strategy. Additional high-priority ports across Europe for potential locations to deploy its modular waste-to-fuel infrastructure include Algeciras, Barcelona, Genoa, Marseille, Le Havre, Antwerp, Rotterdam, Bremen, Immingham, Gdansk, Gothenburg, and Varna.

“Europe currently pays billions to manage waste while remaining reliant on imported energy commodities,” said Reginald Fubara, CEO of HyOrc Corporation. “We close that loop.”

Capital Backing and European Scale HyOrc’s Portuguese joint venture recently secured approval for a €6.7 million non-dilutive grant under the European Union STEP-Programme to support its Phase-2 expansion to 35-TPD of RDF input (~8-TPD methanol output). Additionally, HyOrc and its Bulgarian partner have applied for a €50 million EU Innovation Fund grant.

About HyOrc Corporation
HyOrc Corporation (OTCQB: HYOR) develops and commercializes patented hydrogen-capable combustion and waste-to-fuel systems for the shipping, rail, and off-grid power sectors.

Website: www.hyorc.com Press Contact: comms@hyorc.com

Forward-Looking Statements
This release contains forward-looking statements under Sections 27A and 21E of the Securities Acts of 1933 and 1934. These statements involve risks and uncertainties that may cause actual results to differ materially. Factors are described in Company filings with the SEC. The Company undertakes no obligation to update such statements.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/bcc154f0-7bb7-4e04-9894-4fb9307a68be

https://www.globenewswire.com/NewsRoom/AttachmentNg/362b3809-dd33-44be-9ad6-9cb35b6e1ba1 

https://www.globenewswire.com/NewsRoom/AttachmentNg/2479165a-be93-47e5-83ee-4edbb3442774

Integrated flood risk and property valuation solution advances recurring revenue strategy and supports expansion across markets

DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics, today announced a three-year subscription agreement with Colonnade Insurance S.A. (“Colonnade”) for an integrated flood risk and property valuation solution. Colonnade is a Luxembourg-based non-life insurance company owned by Fairfax Financial Holdings, a Canadian international financial services holding company listed on the Toronto Stock Exchange. Through its subsidiaries, Fairfax is engaged in property, liability and casualty insurance, reinsurance and investment management. The agreement advances Intermap’s strategy to scale recurring insurance analytics solutions across global markets.

The solution enables Colonnade to assess flood exposure, market value and replacement value within a single operational workflow using detailed, current and traceable property information.

“Insurance is a global growth market for Intermap, and this agreement demonstrates how our model scales,” said Patrick A. Blott, Chairman and CEO of Intermap Technologies. “Intermap is increasingly providing valuable business intelligence solutions that leverage our proprietary global geospatial data, software and expertise. We solve complex business problems by transforming geospatial information into recurring subscription solutions that can be deployed across customers, portfolios and geographies. The Colonnade deployment combines immediate operational value with a path to broader adoption, reflecting how we intend to grow our commercial insurance business worldwide.”

The agreement illustrates how Intermap applies its global geospatial intelligence and analytics to solve market-specific challenges for insurers across jurisdictions. The solution is designed to strengthen residential underwriting, portfolio review and customer-facing insurance processes while reducing the need to reconcile information from separate sources.

“Establishing an appropriate insured value is fundamental to protecting our clients,” said Marián Bátovský, CEO of Colonnade Insurance in the Czech Republic. “Combining property valuation and flood exposure in one digital workflow supports more consistent underwriting today and provides a scalable foundation as our business develops across markets.”

The subscription begins in the Czech Republic, with planned expansion into Slovakia and Hungary in 2027. Intermap and Colonnade have established an objective of extending the offering more broadly across Colonnade’s operations in Central and Eastern Europe by 2028, providing a defined path from an initial deployment to multi-country adoption.

Recent natural catastrophes, including volcanic activity in Indonesia, a major earthquake in Colombia and catastrophic flooding in Nepal, underscore the critical need for timely, location-specific risk intelligence. These events demonstrate the importance of geospatial intelligence in supporting disaster preparedness and response, guiding development and infrastructure decisions and helping governments, insurers and businesses allocate capital and resources efficiently and effectively.

Property insurers worldwide require reliable hazard intelligence and current valuation data to establish appropriate coverage, identify potential underinsurance and manage concentrations of risk across diverse portfolios. Munich Re’s NatCatSERVICE estimates that natural disasters caused approximately US$224 billion in global losses during 2025, of which insurers covered approximately US$108 billion. Intermap’s combined offering supports online market valuation of residential units, replacement value calculations for family homes and consistent property-level analysis across insurance workflows.

Swiss Re Institute reports that global insured natural catastrophe losses have increased by 5% to 7% annually in real terms over the long term, driven primarily by rising exposure and costs. Intermap’s insurance solutions combine proprietary, public and commercially available datasets with a 3D data foundation spanning more than 300 million square kilometers across more than 150 countries. This global foundation enables the Company to deliver location-specific risk intelligence for underwriting, accumulation management and portfolio monitoring through a repeatable enterprise subscription model.

Learn more about Intermap’s global insurance solutions here.

Intermap Reader Advisory

Certain information provided in this news release, including references to the planned expansion of Intermap’s Flood Risk and Property Valuation Analytics solution to additional Colonnade Insurance S.A. operations, broader adoption of the solution, the scalability of Intermap’s insurance platform, growth in recurring subscription revenue and the expansion of Intermap’s commercial insurance business globally, constitutes forward-looking statements. The words “anticipate,” “expect,” “project,” “estimate,” “forecast,” “will,” “would,” “may,” “plan,” “intend,” “grow,” “expand,” “scale” and similar expressions are intended to identify such forward-looking statements. Although Intermap believes these statements are based on information and assumptions that are current, reasonable and complete, they are necessarily subject to a variety of known and unknown risks and uncertainties. Intermap’s forward-looking statements are subject to risks and uncertainties pertaining to, among other things, customer adoption, the timing and scope of planned deployments, the Company’s ability to commercialize and scale solutions across markets, cash available to fund operations, availability of capital, revenue fluctuations, the nature of government contracts, economic conditions, loss of key customers, retention and availability of executive talent, competing technologies, common share price volatility, loss of proprietary information, software functionality, internet and system infrastructure functionality, information technology security, breakdown of strategic alliances and international and political considerations, as well as the risks and uncertainties discussed in Intermap’s Annual Information Form and other securities filings. While the Company makes these forward-looking statements in good faith, should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary significantly from those expected. Accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur or, if any of them do, what benefits the Company will derive from them. All subsequent forward-looking statements, whether written or oral, attributable to Intermap or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements contained in this news release are made as of the date of this news release. The Company does not undertake any obligation to update publicly or revise the forward-looking statements made herein, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law.

About Colonnade Insurance S.A.
Colonnade Insurance S.A. is a Luxembourg-based non-life insurance company wholly owned by Fairfax Financial Holdings Limited. The company was established to support Fairfax’s strategic expansion of its insurance business in Central and Eastern Europe.

About Intermap Technologies
Intermap Technologies is a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics. The Company delivers actionable intelligence to government and commercial customers through a portfolio of applications, platforms and solutions supporting risk management, infrastructure planning, operational readiness and mission-critical decision-making. Intermap’s proprietary 3D data foundation spans more than 300 million square kilometers across more than 150 countries and powers intelligence solutions for government, insurance, aviation, telecommunications, transportation, renewable energy, agriculture, natural resources and space markets. Through advanced analytics, automated processing and enterprise-scale data delivery, Intermap helps organizations transform complex geospatial information into decision-ready intelligence.

For more information, please visit www.intermap.com or contact:
Jennifer Bakken
Executive Vice President and CFO
CFO@intermap.com
+1 (303) 708-0955

Sean Peasgood
Investor Relations
Sean@SophicCapital.com
+1 (647) 260-9266

MONTREAL, Sept. 21, 2026 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has finalized and agreed to settlement terms between Prime, Roynat Inc. (“Roynat”), and Financement Agricole Canada (“FAC” together with Roynat, the “Creditors”) and has completed a one-time cash payment of $1,010,000 to the Creditors (the “Settlement Payment”). As a result of the Settlement Payment, the Company has been released by the Creditors from all guarantees made by the Company related to loans extended to Triani Canada Inc., which represented potential exposure to the Company of up to $17.6 million.

Jean Gosselin, Chief Financial Officer of Prime, commented: “The completion of this settlement represents an important milestone for Prime. It allows us to turn the page on a significant source of uncertainty and focus our efforts fully on the next phase of our growth strategy. With the proposed acquisition of Beach Day Every Day, a premium brand that is experiencing success in Québec, together with our strategic partnership with Geloso, we are particularly well positioned to accelerate the development of BDED across the rest of Canada, the United States and Europe. We are very enthusiastic about the opportunities ahead for Prime and our shareholders.”

The completion of the Settlement Payment, together with the anticipated completion of the ongoing private placement financing as announced on August 26, 2026, will enable Prime to strengthen its balance sheet and allow the Company to better focus its resources on achieving its strategic and operational objectives.

About Prime Drink Group
Prime Drink Group Corp (CSE: PRME) is a Québec-based corporation focused on becoming a leading diversified holding company in the beverage, influencer media and hospitality sectors.

For further information, please contact:
Jean Gosselin, CFO
Phone: (514) 394-7717
Email: info@prime-group.ca

Forward-Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations (including negative and grammatical variations) of such words and phrases or statements that certain acts, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information in this press release may include, without limitation, statements relating to the completion of the private placement, and the anticipated benefits to the business of Prime due to the completion of the Settlement Payment.

These statements are based upon assumptions that are subject to significant risks and uncertainties, including risks regarding the beverage industry, market conditions, general economic factors, and the equity markets generally. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance of Prime may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although Prime believes that the expectations reflected in forward-looking statements are reasonable, they can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, Prime disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin syndrome patients and concluding further development of nodular Basal Cell Carcinoma

PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it will focus future internally sponsored clinical development of SkinJect® exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and conclude further development in sporadic/nodular basal cell carcinoma (“nBCC”).

The decision represents a further implementation of the Company’s capital-efficient portfolio strategy announced on September 8, 2026, under which Medicus is concentrating capital and organizational resources on programs where focused clinical development may offer the most compelling risk-adjusted opportunity. In that strategic update, the Company identified Gorlin syndrome, an autosomal dominant rare disease, presenting with multiple basal cell carcinoma lesions, as the strongest development opportunity for SkinJect®.

The Company has now completed a comprehensive assessment incorporating findings from an independent third-party commercial assessment commissioned by the Company, clinical input from Babar K. Rao, MD, FAAD, Clinical Associate Professor of Dermatology at Weill Cornell Medical College and Principal Investigator of the SkinJect® Phase 2 program (SKNJCT-003), findings from the final Phase 2 SkinJect® Clinical Study Report (CSR) and feedback from the U.S. Food and Drug Administration’s Office of Orphan Products Development (“OOPD”) regarding the Company’s requests for Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation (“RPDD”).

Taken together, these inputs support Medicus’s decision to concentrate SkinJect® clinical development and capital allocation exclusively on Gorlin syndrome opportunity.

Management Commentary

“Our September 8 strategic update established a clear principle for Medicus: we intend to concentrate capital where focused clinical development can create the greatest risk-adjusted value. Today’s decision applies that discipline directly to SkinJect®,” stated Dr. Raza Bokhari, Executive Chairman and CEO of Medicus. “Patients with Gorlin syndrome may face a lifetime of recurrent basal cell carcinomas and repeated procedures. We believe the FDA-authorized, NDA-enabling, Registrational SKNJCT-005 study provides us with a focused path to evaluate whether SkinJect® can offer a meaningful lesion-directed treatment option for these patients, while we continue working with the FDA to address the issues identified in our ODD and RPDD designation requests.”

FDA Feedback and Rare-Disease Strategy

In its feedback on the Company’s ODD and RPDD designation requests, the OOPD stated that it considers BCC occurring in Gorlin syndrome to be the same disease as sporadic BCC and noted that the overall prevalence of BCC exceeds the statutory prevalence threshold applicable to the designation requests. The OOPD further identified SkinJect®’s prior clinical development in BCC outside of Gorlin syndrome as relevant to its assessment of whether the program could satisfy applicable orphan-subset requirements.

The FDA has not closed either regulatory pathway. The OOPD held further review of both requests in abeyance pending receipt of additional information from the Company and provided the Company an opportunity to respond.

Medicus believes that focusing future SkinJect® clinical development exclusively on Gorlin syndrome is responsive to the issues identified by the OOPD regarding the Company’s prior development of D-MNA in BCC outside of Gorlin syndrome and provides a more coherent basis for the Company’s continued pursuit of ODD and RPDD designation. The Company intends to continue to engage with the FDA and submit additional information to the OOPD.

The OOPD also advised the Company that, irrespective of the status of the RPDD designation request, if Medicus believes SkinJect ultimately satisfies the statutory requirements for a Rare Pediatric Disease Priority Review Voucher (“PRV”), a voucher request may be included in the original marketing application together with the relevant FDA correspondence and supporting information.

If ODD is ultimately granted and applicable requirements are satisfied, potential benefits may include certain clinical-development tax incentives, exemption from certain FDA application user fees and up to seven years of U.S. orphan-drug exclusivity following approval. If SkinJect ultimately receives a qualifying approval and satisfies all statutory requirements under the RPDD program, the sponsor could potentially receive a transferable PRV.

There can be no assurance that the FDA will ultimately grant either of these designations.

FDA-Authorized, NDA-Enabling, SkinJect® Gorlin Development Program

As previously disclosed on July 27, 2026, the FDA issued a “Study May Proceed” letter to the Company authorizing the initiation of its SKNJCT-005, NDA-enabling Phase 2b study of SkinJect in patients with Gorlin syndrome, an autosomal dominant rare disease, presenting with multiple BCC lesions.

The Gorlin program builds upon the Company’s completed SKNJCT-003 Phase 2 study, which identified the 200-µg doxorubicin-loaded dissolvable microneedle array (“D-MNA”) patch as the proposed pivotal development dose.

Gorlin syndrome is characterized by the development of multiple and recurrent BCCs, which can result in substantial lifetime treatment burden from repeated surgery and other lesion-directed interventions. The Company believes SkinJect®’s localized microneedle-array delivery approach has the potential, if approved, to provide a localized lesion-directed treatment option for this population. Approximately 11,000 patients in the United States with Gorlin syndrome are estimated to have active BCC, representing approximately 50,000 Gorlin-associated BCC procedures annually.

The Gorlin-focused strategy may also potentially support a differentiated reimbursement profile. A Company-commissioned 2026 independent commercial assessment incorporating interviews with physicians and payers modeled rare-disease-anchored net pricing of approximately $25,800 per treatment, an implied U.S. total addressable market of approximately $1.1 billion, and potential peak U.S. revenue of approximately $383 million. These estimates are non-risk-adjusted and dependent upon successful clinical development, regulatory approval, reimbursement and commercial adoption.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations 
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.

The Company’s current therapeutic assets are:

CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer’s established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.

SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.

Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.

Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking statements” or “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, “forward-looking statements”). “Forward-looking statements” are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the development of SkinJect® and the potential benefits thereof for those suffering with Gorlin Syndrome, the Company’s interpretation and characterization of the final SKNJCT-003 CSR data, the selection of the 200-mcg dose as the proposed pivotal dose, the Company’s strategy to prioritize continued clinical development of SkinJect® in Gorlin syndrome, the initiation, conduct and results of SKNJCT-005, the Company’s decision to develop SkinJect® exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and conclude further development in sporadic/nodular basal cell carcinoma, whether the FDA will grant Orphan Drug Designation or Rare Pediatric Disease designation for SkinJect® in Gorlin Syndrome and the benefits of any such designation, if granted, whether the Company will request, and ultimately qualify for, a Rare Pediatric Disease priority review voucher, the potential pricing of, and reimbursement for, SkinJect®, if approved, the estimated number of U.S. Gorlin syndrome patients with active basal cell carcinoma, the estimated annual volume of Gorlin-associated basal cell carcinoma procedures and the estimates of net price per treatment, total addressable market and potential peak U.S. revenue described in this news release, the development of Teverelix® and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix® for AURr, cardiovascular high-risk advanced prostate cancer, women’s health indications like endometriosis, the Company’s co-development with Pfizer with respect to CD228V and the anticipated benefits thereof, the Company’s plans and expectations relating to the development, manufacture and commercialization of CD228V across human therapeutic indications, including the Company’s intention to focus initial development on melanoma with potential subsequent development in squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and esophageal cancer, the timing, design, conduct and results of any future clinical study of CD228V, and the potential market opportunities related to CD228V, SkinJect® and Teverelix® and the Company’s other therapeutic assets. Forward-looking statements are often, but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2025, and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

• Valour launches Valour Funds SPC, a new business line expanding its offering beyond exchange traded products into actively managed digital asset investment strategies.
• Smart Crypto Fund SP is its first hedge fund, providing professional and qualified investors with an actively managed strategy powered by Neuronomics’ proprietary AI strategy.
• The fund builds on Valour’s range of over 100 digital asset ETPs, more than any other digital asset manager globally, and combines Valour’s institutional infrastructure with Neuronomics’ systematic investment expertise.

TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) — DeFi Technologies Inc. (the “Company” or “DeFi Technologies”) (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B) (B3: DEFT31), a financial technology company bridging the gap between traditional capital markets and decentralized finance (“DeFi”), is pleased to announce that its subsidiary, Valour Inc., “Valour”), a leading issuer of exchange traded products (“ETPs”) has launched Valour Funds SPC (“Valour Funds”), a new business line focused on actively managed digital asset investment strategies.

Through Valour Funds, a wholly owned subsidiary of Valour Inc., the new business line is introducing Smart Crypto Fund SP, its first Hedge Fund, providing professional and qualified investors with access to an actively managed investment strategy based on artificial intelligence.

The Hedge Fund expands Valour’s investment platform beyond exchange traded products into actively managed investment solutions. It combines Valour’s institutional fund platform and digital asset infrastructure with a strategy developed and managed by Neuronomics AG, a Swiss portfolio manager specializing in artificial intelligence and systematic investing.

Smart Crypto Fund SP has been established as the first Hedge Fund portfolio of Valour Funds SPC, a Cayman Islands company registered with the Cayman Islands Monetary Authority (“CIMA”). The strategy uses proprietary AI models to adjust allocations across a regularly reviewed selection of liquid digital assets, rather than maintaining fixed exposure to a single cryptocurrency or a static basket.

“With the Smart Crypto Fund, we are expanding Valour’s investment offering beyond exchange traded products and into actively managed hedge fund strategies,” said Johan Wattenström, CEO and Chairman of DeFi Technologies. “By combining Valour’s digital asset infrastructure with Neuronomics’ AI based systematic investment expertise, we can offer professional investors an actively managed strategy within an institutional fund framework.”

AI Driven Systematic Investment Strategy

Digital asset markets offer a broad range of investment opportunities. However, they also experience significant volatility, rapidly changing conditions and substantial differences in liquidity and risk across individual assets.

The Hedge Fund is not designed to maintain a fixed allocation or remain fully exposed to the market at all times. Instead, it seeks to invest selectively when the expected balance of opportunity and risk is favorable. It also seeks to reduce exposure when model signals weaken or assessed risk increases.

Neuronomics’ proprietary AI ensemble, a group of complementary models, is central to this approach. The models analyze price, volume and other market data over short and medium time horizons. They seek to distinguish useful signals from market noise and assess potential returns, risk and market conditions.

These assessments guide the size of each position across a regularly reviewed selection of liquid digital assets. Portfolio allocations remain subject to predefined risk budgets, limits on individual assets and concentration, and controls on overall market exposure.

Trading instructions are executed using algorithms selected according to market liquidity and expected transaction costs. This disciplined process is designed to capture investment opportunities while actively managing the volatility and downside risks of digital asset markets.

“Digital asset markets generate enormous volumes of rapidly changing information, but the challenge is determining which signals matter, over what horizon and under which market conditions,” said Dr. Michael Kometer, Founder and CEO of Neuronomics AG. “Our proprietary AI ensemble helps separate signal from noise and translates forecasts into disciplined portfolio decisions. It guides what we hold, how much risk we take and when we reduce exposure.”

Institutional Infrastructure

Smart Crypto Fund SP brings together Valour’s digital asset platform, Neuronomics’ investment management capabilities and a network of specialist service providers covering fund administration, custody, banking, execution and audit.

The structure separates investment management, administration, custody and execution. This provides the operational framework required for a professionally managed digital asset investment fund.

The Launch Marks Valour’s Expansion into the Hedge Fund Segment

Valour offers over 100 digital asset ETPs, more than any other digital asset manager globally. These products give investors access to the world’s most innovative digital asset ecosystems through regulated markets.

Smart Crypto Fund complements this offering with an actively managed Hedge Fund for professional and qualified investors. The fund uses a systematic investment approach to identify opportunities across the digital asset market.

About Neuronomics AG
Neuronomics AG is a FINMA authorized Swiss portfolio manager and a pioneer in applying artificial intelligence to the professional management of digital assets. DeFi Technologies holds a minority stake in the company.

Its proprietary research combines artificial intelligence, quantitative finance and computational neuroscience to develop market forecasts. These forecasts guide portfolio allocations within disciplined risk controls. For more information, visit www.neuronomics.com.

About Valour Funds SPC
Valour Funds SPC is a Cayman Islands company and a wholly owned subsidiary of Valour Inc. The company has been established to provide professionally managed investment strategies focused on digital assets and related investment opportunities.

Smart Crypto Fund SP is the first Hedge Fund established under Valour Funds SPC.

About DeFi Technologies
DeFi Technologies Inc. (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B) (B3:DEFT31) is a financial technology company building for the convergence of traditional capital markets and decentralized finance (“DeFi”). As a publicly listed and vertically integrated digital asset platform, DeFi Technologies provides familiar, simple, secure, and regulated access to the digital asset economy through investment products, trading and liquidity infrastructure, research, and strategic capital deployment. Its business includes Valour, a leading issuer of regulated digital asset ETPs; Stillman Digital, an institutional-grade digital asset trading and liquidity platform; and DeFi Alpha, the Company’s internal business line focused on opportunistic trading, arbitrage, and other capital markets strategies. With deep expertise across capital markets and emerging technologies, DeFi Technologies is building the gateway between traditional finance and the future of digital assets. Follow DeFi Technologies on LinkedIn and X/Twitter, and for more details, visit https://defi.tech/  

DeFi Technologies Subsidiaries

About Valour
Valour Inc. and Valour Digital Securities Limited (together, “Valour”) issues exchange traded products (“ETPs”) that enable retail and institutional investors to access digital assets in a simple and secure way via their traditional bank account. Valour is part of the asset management business line of DeFi Technologies. For more information about Valour, to subscribe, or to receive updates, visit https://valour.com.

About Stillman Digital
Stillman Digital is a leading digital asset liquidity provider that offers limitless liquidity solutions for businesses, focusing on industry-leading trade execution, settlement, and technology. For more information, please visit https://www.stillmandigital.com

Cautionary note regarding forward-looking information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to proposed listing of Valour’s ETPs and DeFi Technologies’, the expected timing of listing and trading, and anticipated investor demand for digital asset ETPs; the regulatory environment with respect to the growth and adoption of decentralized finance; the pursuit by the Company and its subsidiaries of business opportunities; and the merits or potential returns of any such opportunities. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Such risks, uncertainties and other factors include, but is not limited the acceptance of Valour exchange traded products by exchanges; growth and development of decentralised finance and digital asset sector; rules and regulations with respect to decentralised finance and digital assets; fluctuation in digital asset prices; general business, economic, competitive, political and social uncertainties. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

THE CBOE CANADA EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

For further information, please contact:

Johan Wattenstrom
Chief Executive Officer
ir@defi.tech
(323) 537-7681

HAMBURG, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) — XCHG Limited (“XCharge” or the “Company”) (Nasdaq: XCH), a global provider in high-power EV charging solutions, today informs that EnBW, operator of Germany’s largest fast-charging network, has launched the new XCharge C7 high-power charger within its nationwide fast charging network. The C7 chargers are now in operation at EnBW’s flagship charging site at its headquarters in Karlsruhe, Germany, as well as the EnBW fast charging hub in Nettetal near the Dutch border. Delivering up to 480 kW of charging power, the C7 is designed to support the next generation of electric vehicles with ever-higher charging capabilities.

XCharge C7 480 kW chargers at EnBW’s flagship charging site at its headquarters in Karlsruhe, Germany

Photo credit: EnBW / Photographer: Endre Dulic

The deployment follows the long-term partnership announced by EnBW and XCharge in February 2026. The agreement was based on a successful field test in which XCharge charging stations demonstrated their reliability, performance, and safety across tens of thousands of charging sessions.

XCharge C7 480 kW in operation at EnBW’s flagship charging site at its headquarters in Karlsruhe, Germany

Photo credit: EnBW / Photographer: Endre Dulic

Albina Iljasov, Co-CEO of XCharge, said: “With the new C7, we have introduced a product to the European market that reliably meets the demanding technical requirements of charging network operators and their customers. We are pleased that our technology will now be deployed on an ongoing basis throughout EnBW’s fast charging network, allowing us to contribute to the continued advancement of electric mobility in Germany.”

Targeted Deployment Along Long-Distance Travel Routes

“Electric mobility will continue to develop rapidly over the coming years. That’s why we’re not only expanding our fast charging network in terms of scale, but also investing specifically in new charging technology that meets both our own high standards and the expectations of our customers. With XCharge’s new 480 kW charging systems, EV drivers in the EnBW charging network benefit from short charging times, advanced technology, and high reliability,” said Lars Jacobs, CCO and Acting CTO of EnBW’s e-mobility division.

EnBW already operates more than 9,000 fast charging points across Germany and continues to expand its network in line with demand across three key segments: long-distance travel, urban areas, and retail locations. Charging infrastructure requirements vary depending on the location.

“The new 480 kW charging technology will primarily be deployed at locations where customers typically spend only a short time and want to add as much driving range as possible during their stop—for example, at EnBW fast charging parks along Germany’s major highways,” Jacobs added.

Depending on the vehicle, the new 480 kW charging technology can deliver up to 640 km of driving range in just 20 minutes. EV drivers also benefit from the higher charging capacity through dynamic power allocation when two vehicles charge simultaneously at the same station. Depending on each vehicle’s charging capabilities, this can significantly reduce charging times and maximize charging performance.

By the end of 2026, EnBW plans to bring a further double-digit number of fast charging parks equipped with XCharge’s C7 480 kW charging technology online across Germany, marking another step in the continued expansion of one of Europe’s largest fast charging networks.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “objective,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the United States Securities and Exchange Commission.

All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

About XCharge

XCharge (Nasdaq: XCH) is a global provider in high-power electric vehicle charging solutions. The Company has headquarters in Hamburg, Germany and Austin, TX, working with a globally networked team to drive innovation in the field of energy and help its customers achieve long-term success.

For investor and media inquiries, please contact:
XCHG Limited
IR Department
Email: ir@xcharge.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/0993038d-8c78-4fbe-8ccd-e0922363f68e
https://www.globenewswire.com/NewsRoom/AttachmentNg/eca903bc-6a94-4421-9305-162f104a245e

• Event to be hosted on November 3, 2026 at 8:00 AM EST
• Featured speakers will include Peter A. Merkel, MD, MPH and Prof. Dr. Jörg Köhl

Jena, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) —  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST / 2:00 PM CET to approximately 9:00 AM EST / 3:00 PM CET. The timing of the event has been shifted to better accommodate scheduling and the Company’s clinical development planning processes in ANCA-associated vasculitis (AAV).

Featuring leading experts in the fields of AAV and complement inhibition, the virtual event will provide an overview of the evolving treatment landscape and unmet need in AAV, and how izicopan’s differentiated chemistry, metabolic properties, and potential safety advantages could improve upon the existing standard of care in AAV.

The event will also provide updated thinking on InflaRx’s development strategy in AAV, including an overview of the anticipated clinical program. The event will feature presentations from members of InflaRx’s management team and invited external experts, followed by a question-and-answer session.

Featured key opinion leaders will include:

Peter A. Merkel, MD, MPH, Chief, Division of Rheumatology; Professor of Medicine (Rheumatology); Professor of Epidemiology in Biostatistics and Epidemiology; University of Pennsylvania, Philadelphia, PA USA

Prof. Dr. Jörg Köhl, Director of the Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany

The Capital Markets Event will take place on Tuesday, November 3, 2026, from 8:00 AM EST / 2:00 PM CET to approximately 9:00 AM EST / 3:00 PM CET. To participate in the virtual event, participants are requested to pre-register here to receive an invite link and dial-in details to access the event. 

About the speakers

Peter A. Merkel, MD, MPH

Chief, Division of Rheumatology; Professor of Medicine (Rheumatology); Professor of Epidemiology in Biostatistics and Epidemiology; University of Pennsylvania, Philadelphia, PA, USA

Dr. Merkel is an internationally leading clinical and research expert in vasculitis, with particular expertise in the clinical investigation and treatment of AAV.

Dr. Merkel is the Chief of Rheumatology and a Professor of Medicine and Epidemiology at the University of Pennsylvania. Dr. Merkel is an internationally recognized researcher and clinical expert in vasculitis, scleroderma, and other systemic autoimmune diseases, and is an author on over 500 scientific publications. He is the Principal Investigator of the Vasculitis Clinical Research Consortium (VCRC) and the Vasculitis Patient-Powered Research Network (VPPRN), two leading international research infrastructures for clinical investigation in vasculitis, and is the co-Director of the newly established International Vasculitis Network (IVN). Dr. Merkel has led major clinical trials in AAV, including research on avacopan and other glucocorticoid-sparing treatment strategies. His research focuses on development of novel therapies for systemic autoimmune diseases, clinical trial design and conduct, outcome measure development, clinical epidemiology, genetic epidemiology, and biomarker discovery. Dr. Merkel received the 2023 Distinguished Clinical Scientist Award from the American College of Rheumatology.

Prof. Dr. Jörg Köhl

Director of the Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany

Dr. Köhl is a globally renowned translational complement scientist with a particular focus on the role of C5a/C5aR biology and its role in human disease.

He has over 35 years of medical and research experience and has published over 200 papers in the complement therapeutic landscape. His research has been continuously funded by the National Institutes of Health, the German Research Foundation, the Federal Ministry of Education and Research and the European Union since 1990. He has held several senior scientific positions, including a 20-year research appointment as Professor of Pediatrics at Cincinnati Children’s Hospital Medical Center in the Divisions of Molecular Immunology and Immunobiology and his current position as the Founding Director of the Institute for Systemic Inflammation Research at the University of Lübeck, Germany. Dr. Köhl received his medical degree from the University of Mainz, Germany.

About izicopan
Izicopan is an orally administered, small molecule inhibitor of the C5a receptor (C5aR) that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. Further, in contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan does not exhibit time-dependent inhibition of cytochrome P450 3A4 (CYP3A4), which plays an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Izicopan has also demonstrated a favorable reactive metabolite profile in human liver microsomes. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day to 90 mg twice per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period. Topline Phase 2a data further support the safety profile of izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels, robust HiSCR responses that continued to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved disease control as measured by the Urticaria Control Test (UCT7). In addition, InflaRx is planning for development of izicopan in ANCA-associated vasculitis and additional renal indications.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Common shares are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company, simplifying the process of trading and enhancing liquidity of the Company’s shares in the United States

Vancouver, BC, Sept. 21, 2026 (GLOBE NEWSWIRE) — SalesCloser Technologies Ltd. (“SalesCloser” or the “Company”) (TSXV: SCAI) (OTCQB: SCTLF) (FSE: MJ5), a pioneer in autonomous AI sales technology, is pleased to announce that its common shares are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company (“DTC”).

DTC is a subsidiary of The Depository Trust & Clearing Corporation (“DTCC”) and manages the electronic clearing and settlement of publicly traded securities in the United States. Securities eligible for electronic clearing and settlement through DTC are considered to be “DTC eligible” and may be traded through participating brokerage firms using electronic book-entry transfers, without the need for physical share certificates. DTC eligibility is expected to simplify the process of trading and enhance liquidity of the Company’s common shares in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and accelerates the settlement process for investors and brokers, reduces administrative cost, and enables the stock to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements.

The Company’s common shares commenced trading on the OTCQB Venture Market under the symbol “SCTLF” on July 7, 2026, and continue to trade on the TSX Venture Exchange under “SCAI” and on the Frankfurt Stock Exchange under “MJ5”. DTC eligibility completes the operational groundwork behind the Company’s U.S. quotation, making it more straightforward for U.S. investors to hold and trade SalesCloser common shares through their existing brokerage relationships and making the Company’s shares more accessible to the U.S. investment community. Existing shareholders are not required to take any action as a result of the Company’s common shares becoming DTC eligible.

“Our shares have been quoted in the United States since July, and DTC eligibility is the step that makes holding them as routine as any other position in a U.S. brokerage account,” said Ali Tajskandar, Chief Executive Officer of SalesCloser. “As our commercial footprint expands across North America, we want the mechanics of owning the stock to be a non-issue for investors who want exposure to what we are building.”

About SalesCloser
SalesCloser.ai is a Vancouver-based AI software company focused on automating and scaling revenue generation through conversational AI. The Company’s platform enables businesses to deploy AI-powered virtual sales agents that engage prospects and customers across the sales lifecycle. SalesCloser’s agents conduct real-time, personalized interactions across voice, video, and digital channels, including lead qualification, product demonstrations, follow-ups, and meeting scheduling. By augmenting core sales functions, the platform helps organizations increase capacity, accelerate pipeline velocity, and improve conversion rates without a corresponding increase in headcount. The platform integrates with existing CRM and business systems, supports multilingual deployment, and delivers consistent, high-quality customer interactions across industries. SalesCloser operates under a subscription-based SaaS model, generating recurring revenue with strong visibility and high gross margins while continuously enhancing its AI capabilities. The Company’s technology is supported by a growing portfolio of patents and patent applications focused on improving the performance of AI-driven conversational workflows. SalesCloser.ai is listed on the TSX Venture Exchange under the ticker “SCAI”, on the OTCQB Venture Market under the ticker “SCTLF”, and on the Frankfurt Stock Exchange under the ticker “MJ5”. For more information, visit the SalesCloser investor site at: https://investors.salescloser.ai

Corporate Contact
Adrian Lim, CFO
Email: investors@salescloser.ai
Phone: 778 655 4329

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
SCAI@arxhq.com

Forward-Looking Statements
Statements that are not reported financial results or other historical information are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”). This press release includes forward-looking statements regarding the Company, its subsidiaries and the industries in which they operate, including statements about and references to the anticipated benefits of DTC eligibility, including the simplification of the process of trading, enhanced liquidity of the Company’s common shares in the United States, accelerated settlement timelines, reduced administrative cost and friction for investors and broker-dealers, broader access to the Company’s common shares through U.S. brokerage firms, and greater accessibility of the Company’s shares to the U.S. investment community, the anticipated benefits of the Company’s quotation on the OTCQB Venture Market and its listings on the TSX Venture Exchange and the Frankfurt Stock Exchange, the Company’s plans to increase its visibility and accessibility within the United States capital markets, expected results from future operations, future growth of the Company’s products and platforms, the future development and increased use of products incorporating artificial intelligence, technology development initiatives, future profitability, business and acquisition strategies, opportunities, objectives, prospects, the impact of broader economic factors on the Company, and future events and performance. Sentences and phrases containing or modified by words such as “expect”, “anticipate”, “plan”, “continue”, “estimate”, “intend”, “may”, “will”, “project”, “predict”, “potential”, “targets”, “is designed to”, “strategy”, “should”, “believe”, “contemplate” and similar expressions, and the negative of such expressions, are not historical facts and are intended to identify forward-looking statements. Readers are cautioned to not place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by forward-looking statements. Although the Company believes that the expectations reflected in forward-looking statements in this press release are reasonable and are based on, among other things, the expectations and analysis of current market trends and opportunities of management of the Company, such forward-looking statements have been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including, but not limited to, the Company’s continued ability to satisfy applicable DTC, OTCQB, TSX Venture Exchange and other regulatory requirements, the willingness of brokerage firms, custodians and institutional platforms to support trading in the Company’s common shares, market demand and investor interest, trading activity and liquidity in the Company’s common shares, changes to SalesCloser and other product’s revenue and profitability, changes to customer preferences, competition, use cases for SalesCloser and other products, economic uncertainty and instability as a result of the ongoing inflation and supply chain issues, higher interest rate climate, tightening of credit availability and recessionary risks, pandemic related risks, wars, tariffs, instability in global commodity and securities markets, shifts in consumer and institutional spending and marketing strategies, risks related to data breaches and privacy, the changing global market and competition for the products and services supplied by the Company, and the additional risk factors discussed in the continuous disclosure materials of the Company which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.